| Year |
Citation |
Score |
| 2023 |
Botros NE, Polinger-Hyman D, Beck RT, Kleefisch C, Mrachek EKS, Connelly J, Schmainda KM, Krucoff MO. Magnetic resonance imaging-derived relative cerebral blood volume characteristics in a case of pathologically confirmed neurocysticercosis: illustrative case. Journal of Neurosurgery. Case Lessons. 6. PMID 38109728 DOI: 10.3171/CASE23446 |
0.316 |
|
| 2023 |
Hu LS, D'Angelo F, Weiskittel TM, Caruso FP, Fortin Ensign SP, Blomquist MR, Flick MJ, Wang L, Sereduk CP, Meng-Lin K, De Leon G, Nespodzany A, Urcuyo JC, Gonzales AC, Curtin L, ... ... Schmainda KM, et al. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nature Communications. 14: 6066. PMID 37770427 DOI: 10.1038/s41467-023-41559-1 |
0.358 |
|
| 2023 |
Hangel G, Schmitz-Abecassis B, Sollmann N, Pinto J, Arzanforoosh F, Barkhof F, Booth T, Calvo-Imirizaldu M, Cassia G, Chmelik M, Clement P, Ercan E, Fernández-Seara MA, Furtner J, Fuster-Garcia E, ... ... Schmainda KM, et al. Advanced MR Techniques for Preoperative Glioma Characterization: Part 2. Journal of Magnetic Resonance Imaging : Jmri. PMID 36912262 DOI: 10.1002/jmri.28663 |
0.333 |
|
| 2023 |
Hirschler L, Sollmann N, Schmitz-Abecassis B, Pinto J, Arzanforoosh F, Barkhof F, Booth T, Calvo-Imirizaldu M, Cassia G, Chmelik M, Clement P, Ercan E, Fernández-Seara MA, Furtner J, Fuster-Garcia E, ... ... Schmainda K, et al. Advanced MR Techniques for Preoperative Glioma Characterization: Part 1. Journal of Magnetic Resonance Imaging : Jmri. PMID 36866773 DOI: 10.1002/jmri.28662 |
0.329 |
|
| 2022 |
Malik DG, Rath TJ, Urcuyo Acevedo JC, Canoll PD, Swanson KR, Boxerman JL, Quarles CC, Schmainda KM, Burns TC, Hu LS. Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions. Frontiers in Radiology. 2: 809373. PMID 37492687 DOI: 10.3389/fradi.2022.809373 |
0.35 |
|
| 2022 |
Amidon RF, Santos-Pinheiro F, Straza M, Prah MA, Mueller WM, Krucoff MO, Connelly JM, Kleefisch CJ, Coss DJ, Cochran EJ, Bovi JA, Schultz CJ, Schmainda KM. Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. Frontiers in Oncology. 12: 1066191. PMID 36561526 DOI: 10.3389/fonc.2022.1066191 |
0.354 |
|
| 2021 |
McGarry SD, Brehler M, Bukowy JD, Lowman AK, Bobholz SA, Duenweg SR, Banerjee A, Hurrell SL, Malyarenko D, Chenevert TL, Cao Y, Li Y, You D, Fedorov A, Bell LC, ... ... Schmainda KM, et al. Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness. Journal of Magnetic Resonance Imaging : Jmri. PMID 34767682 DOI: 10.1002/jmri.27983 |
0.588 |
|
| 2021 |
Connelly JM, Prah MA, Santos-Pinheiro F, Mueller W, Cochran E, Schmainda KM. Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report. Neurosurgery Open. 2: okab029. PMID 34661110 DOI: 10.1093/neuopn/okab029 |
0.352 |
|
| 2020 |
Schmainda KM, Prah MA, Marques H, Kim E, Barboriak DP, Boxerman JL. Value of Dynamic Contrast Perfusion MRI to Predict Early Response to Bevacizumab in Newly Diagnosed Glioblastoma: Results from ACRIN 6686 Multi-Center Trial. Neuro-Oncology. PMID 32678438 DOI: 10.1093/Neuonc/Noaa167 |
0.365 |
|
| 2020 |
Bovi JA, Prah MA, Retzlaff AA, Schmainda KM, Connelly JM, Rand SD, Marszalkowski CS, Mueller WM, Siker ML, Schultz CJ. Pulsed reduced dose rate radiotherapy in conjunction with bevacizumab significantly extends survival over bevacizumab alone in recurrent high-grade glioma. International Journal of Radiation Oncology, Biology, Physics. PMID 32599030 DOI: 10.1016/J.Ijrobp.2020.06.020 |
0.366 |
|
| 2020 |
Bell LC, Semmineh N, An H, Eldeniz C, Wahl R, Schmainda KM, Prah MA, Erickson BJ, Korfiatis P, Wu C, Sorace AG, Yankeelov TE, Rutledge N, Chenevert TL, Malyarenko D, et al. Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge. Tomography (Ann Arbor, Mich.). 6: 203-208. PMID 32548297 DOI: 10.18383/j.tom.2020.00012 |
0.349 |
|
| 2020 |
Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, ... ... Schmainda KM, et al. Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. Neuro-Oncology. PMID 32516388 DOI: 10.1093/Neuonc/Noaa141 |
0.409 |
|
| 2020 |
Hoxworth JM, Eschbacher JM, Gonzales AC, Singleton KW, Leon GD, Smith KA, Stokes AM, Zhou Y, Mazza GL, Porter AB, Mrugala MM, Zimmerman RS, Bendok BR, Patra DP, Krishna C, ... ... Schmainda KM, et al. Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies. Ajnr. American Journal of Neuroradiology. PMID 32165359 DOI: 10.3174/Ajnr.A6486 |
0.709 |
|
| 2019 |
Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. Ajnr. American Journal of Neuroradiology. 40: 1132-1139. PMID 31248863 DOI: 10.3174/Ajnr.A6110 |
0.448 |
|
| 2019 |
Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL. Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. Ajnr. American Journal of Neuroradiology. PMID 30923088 DOI: 10.3174/Ajnr.A6015 |
0.69 |
|
| 2019 |
Bell LC, Semmineh N, An H, Eldeniz C, Wahl R, Schmainda KM, Prah MA, Erickson BJ, Korfiatis P, Wu C, Sorace AG, Yankeelov TE, Rutledge N, Chenevert TL, Malyarenko D, et al. Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO). Tomography (Ann Arbor, Mich.). 5: 110-117. PMID 30854448 DOI: 10.18383/j.tom.2018.00041 |
0.639 |
|
| 2019 |
Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, ... ... Schmainda K, et al. The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II. Tomography (Ann Arbor, Mich.). 5: 99-109. PMID 30854447 DOI: 10.18383/j.tom.2018.00027 |
0.597 |
|
| 2019 |
Quarles C, Bell L, Semmineh N, Fuentes A, Prah M, Nespodzany A, Alhilai L, Karis J, Rand S, Dardis C, Braun K, Connelly J, Zhou Y, Schmainda K, Hu L, et al. NIMG-28. VALIDATION OF SINGLE-DOSE DSC-MRI PROTOCOLS FOR ROBUST PERFUSION ASSESSMENT IN BRAIN TUMORS Neuro-Oncology. 21: vi167-vi167. DOI: 10.1093/Neuonc/Noz175.699 |
0.669 |
|
| 2018 |
Alhajala HS, Nguyen HS, Shabani S, Best B, Kaushal M, Al-Gizawiy MM, Erin Ahn EY, Knipstein JA, Mirza S, Schmainda KM, Chitambar CR, Doan NB. Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy genome-wide transcriptome changes. Oncotarget. 9: 34122-34131. PMID 30344926 DOI: 10.18632/Oncotarget.26137 |
0.343 |
|
| 2018 |
Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, et al. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. Plos One. 13: e0198548. PMID 29902200 DOI: 10.1371/Journal.Pone.0198548 |
0.404 |
|
| 2018 |
Doan NB, Nguyen HS, Alhajala HS, Jaber B, Al-Gizawiy MM, Ahn EE, Mueller WM, Chitambar CR, Mirza SP, Schmainda KM. Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model. Oncotarget. 9: 23532-23542. PMID 29805753 DOI: 10.18632/Oncotarget.25247 |
0.313 |
|
| 2018 |
Schmainda KM, Prah MA, Rand SD, Liu Y, Logan B, Muzi M, Rane SD, Da X, Yen YF, Kalpathy-Cramer J, Chenevert TL, Hoff B, Ross B, Cao Y, Aryal MP, et al. Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. Ajnr. American Journal of Neuroradiology. PMID 29794239 DOI: 10.3174/Ajnr.A5675 |
0.72 |
|
| 2018 |
Chitambar CR, Al-Gizawiy MM, Alhajala HS, Pechman KR, Wereley JP, Wujek R, Clark PA, Kuo JS, Antholine WE, Schmainda KM. Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. Molecular Cancer Therapeutics. PMID 29592883 DOI: 10.1158/1535-7163.Mct-17-1009 |
0.373 |
|
| 2018 |
Malyarenko D, Fedorov A, Bell L, Prah M, Hectors S, Arlinghaus L, Muzi M, Solaiyappan M, Jacobs M, Fung M, Shukla-Dave A, McManus K, Boss M, Taouli B, Yankeelov TE, ... ... Schmainda K, et al. Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies. Journal of Medical Imaging (Bellingham, Wash.). 5: 011006. PMID 29134189 DOI: 10.1117/1.Jmi.5.1.011006 |
0.683 |
|
| 2018 |
Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, et al. Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. Journal of Medical Imaging (Bellingham, Wash.). 5: 011003. PMID 29021993 DOI: 10.1117/1.Jmi.5.1.011003 |
0.671 |
|
| 2018 |
Al-Gizawiy M, Robert W, Alhajala H, Cobb J, Prah M, Mirza S, Chitambar C, Schmainda K. EXTH-48. ORAL GALLIUM MALTOLATE IMPAIRS TUMOR GROWTH AND EXTENDS DISEASE-SPECIFIC SURVIVAL IN A XENOGRAFT MODEL OF RECURRENT GBM Neuro-Oncology. 20: vi95-vi95. DOI: 10.1093/Neuonc/Noy148.396 |
0.339 |
|
| 2017 |
Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP. Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. Oncotarget. 8: 112662-112674. PMID 29348854 DOI: 10.18632/Oncotarget.22637 |
0.319 |
|
| 2017 |
Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. Journal of Neuro-Oncology. PMID 28900832 DOI: 10.1007/S11060-017-2617-3 |
0.493 |
|
| 2017 |
Bell LC, Does MD, Stokes AM, Baxter LC, Schmainda KM, Dueck AC, Quarles CC. Optimization of DSC MRI Echo Times for CBV Measurements Using Error Analysis in a Pilot Study of High-Grade Gliomas. Ajnr. American Journal of Neuroradiology. PMID 28684456 DOI: 10.3174/Ajnr.A5295 |
0.667 |
|
| 2017 |
Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP. Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget. 8: 24753-24761. PMID 28445970 DOI: 10.18632/Oncotarget.15800 |
0.392 |
|
| 2017 |
Hurrell S, Cochran E, Mueller WM, McGarry S, Schultz CJ, Siker M, Rand S, LaViolette PS, Schmainda KM, Connelly JM. RARE-16. CASE REPORT: DELAYED DEVELOPMENT OF PSEUDOPROGRESSION IN 2 GLIOBLASTOMA PATIENTS TREATED WITH TTFIELDS Neuro-Oncology. 19: vi214-vi214. DOI: 10.1093/Neuonc/Nox168.866 |
0.57 |
|
| 2017 |
Connelly JM, Prah MA, Schmainda KM. NIMG-67. ADVANCED PERFUSION AND DIFFUSION MR IMAGING IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) AS FIRST-LINE THERAPY Neuro-Oncology. 19: vi157-vi157. DOI: 10.1093/Neuonc/Nox168.640 |
0.44 |
|
| 2017 |
Hurrell S, Cochran E, McGarry S, Connelly JM, Schmainda KM, Rand S, Mueller WM, LaViolette P. ACTR-44. AUTOPSY STUDY ON THE EFFECTS OF TUMOR TREATMENT FIELDS IN RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS AND TRIAL DESIGN Neuro-Oncology. 19: vi10-vi10. DOI: 10.1093/Neuonc/Nox168.035 |
0.647 |
|
| 2017 |
Al-Gizawiy MM, Doan NB, Wujek RT, Alhajala HS, Mirza SP, Chitambar CR, Schmainda KM. TMOD-09. A PATIENT-DERIVED XENOGRAFT MODEL MIMICKING RECURRENT PEDIATRIC MALIGNANT GLIOMA Neuro-Oncology. 19: iv50-iv50. DOI: 10.1093/Neuonc/Nox083.208 |
0.384 |
|
| 2017 |
Schmainda K, Pray M, Palomares J, Maheshwari M, Lew S, Kelly T. HGG-01. A COMBINED PERFUSION AND DIFFUSION MRI BIOMARKER TO DISTINGUISH PEDIATRIC GLIOMA GRADE Neuro-Oncology. 19: iv22-iv22. DOI: 10.1093/Neuonc/Nox083.090 |
0.404 |
|
| 2016 |
Paulson ES, Prah DE, Schmainda KM. Spiral Perfusion Imaging With Consecutive Echoes (SPICE™) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility. Tomography : a Journal For Imaging Research. 2: 295-307. PMID 28090589 DOI: 10.18383/j.tom.2016.00217 |
0.732 |
|
| 2016 |
McGarry SD, Hurrell SL, Kaczmarowski AL, Cochran EJ, Connelly J, Rand SD, Schmainda KM, LaViolette PS. Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy. Tomography : a Journal For Imaging Research. 2: 223-228. PMID 27774518 DOI: 10.18383/j.tom.2016.00250 |
0.679 |
|
| 2016 |
Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. Ajnr. American Journal of Neuroradiology. PMID 27492073 DOI: 10.3174/Ajnr.A4898 |
0.678 |
|
| 2016 |
Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, ... ... Schmainda K, et al. The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge. Tomography : a Journal For Imaging Research. 2: 56-66. PMID 27200418 DOI: 10.18383/j.tom.2015.00184 |
0.622 |
|
| 2016 |
Gerstner E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Prah M, Schmainda K, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak D, et al. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using 18F-FMISO PET and MRI. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185374 DOI: 10.1200/Jco.2015.33.15_Suppl.2024 |
0.409 |
|
| 2016 |
Hurrell S, McGarry S, Cochran E, Connelly JM, Rand S, Bovi J, LaViolette PS, Schmainda KM, Kaczmarowski A. NIMG-53. PREDICTIVE CYTOLOGICAL TOPOGRAPHY MAPS REGIONS OF PATHOLOGICALLY CONFIRMED NON-ENHANCING HYPERCELLULAR TUMOR IN GLIOBLASTOMA PATIENTS Neuro-Oncology. 18: vi136-vi136. DOI: 10.1093/Neuonc/Now212.564 |
0.651 |
|
| 2016 |
McGarry S, Hurrell S, Kaczmarowski A, Cochran E, Connelly JM, Bovi J, Rand S, Schmainda KM, LaViolette PS. NIMG-25. RADIOMIC PROFILING MAPS AREAS OF PATHOLOGICALLY CONFIRMED TUMOR AND PREDICTS OVERALL SURVIVAL IN PRE-TREATMENT GLIOBLASTOMA Neuro-Oncology. 18: vi129-vi129. DOI: 10.1093/Neuonc/Now212.537 |
0.649 |
|
| 2015 |
Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS. Location of brain tumor intersecting white matter tracts predicts patient prognosis. Journal of Neuro-Oncology. 125: 393-400. PMID 26376654 DOI: 10.1007/S11060-015-1928-5 |
0.682 |
|
| 2015 |
Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro-Oncology. 17: 1538-9. PMID 26361983 DOI: 10.1093/Neuonc/Nov163 |
0.349 |
|
| 2015 |
Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM. Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma. Ajnr. American Journal of Neuroradiology. 36: 1654-61. PMID 26066626 DOI: 10.3174/Ajnr.A4374 |
0.361 |
|
| 2015 |
Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Translational Oncology. 8: 137-46. PMID 26055170 DOI: 10.1016/J.Tranon.2015.03.002 |
0.384 |
|
| 2015 |
Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro-Oncology. 17: 1148-56. PMID 25646027 DOI: 10.1093/Neuonc/Nou364 |
0.37 |
|
| 2015 |
Prah M, Connelly J, Schmainda K. NIMG-58PRELIMINARY TRENDS IN ADVANCED IMAGING RELATIVE TO STANDARD IMAGING IN SUBJECTS TREATED WITH OPTUNE Neuro-Oncology. 17: v167.2-v167. DOI: 10.1093/Neuonc/Nov225.58 |
0.43 |
|
| 2015 |
LaViolette P, Milbach N, Connelly J, Rand S, Schmainda K, Cochran E. NIMG-47PATHOLOGICALLY CONFIRMED VIABLE TUMOR SURROUNDS REGIONS OF PROGRESSIVELY EXPANDING DIFFUSION-RESTRICTED NECROSIS FOLLOWING BEVACIZUMAB TREATMENT Neuro-Oncology. 17: v164.3-v164. DOI: 10.1093/Neuonc/Nov225.47 |
0.691 |
|
| 2015 |
Al-Gizawiy M, Prah M, Mueller W, Schmainda K. NIMG-01ADVANCED MR PERFUSION AND DIFFUSION MEASURES DISTINGUISH BETWEEN GLIOMA SUBTYPES Neuro-Oncology. 17: v153.1-v153. DOI: 10.1093/Neuonc/Nov225.01 |
0.488 |
|
| 2015 |
Renu D, Aggarwal P, Cherukuri S, Tata P, Bhat V, Livi C, Rosenberg M, Al-Gizawiy M, Mueller W, Connelly J, Schmainda K, Mirza S. GENO-02INTEGRATED ANALYSIS OF MOLECULAR SUBTYPES IN GLIOBLASTOMA MULTIFORME Neuro-Oncology. 17: v91.2-v91. DOI: 10.1093/Neuonc/Nov215.02 |
0.358 |
|
| 2015 |
Al-Gizawiy M, Pechman K, Lozen A, Wereley J, Chitambar C, Schmainda K. ATPS-02CONTINUOUS ADMINISTRATION OF THE NOVEL IRON-MIMETIC GALLIUM MALTOLATE INHIBITS GLIOMA GROWTHIN VITROANDIN VIVO Neuro-Oncology. 17: v18.2-v18. DOI: 10.1093/Neuonc/Nov204.02 |
0.355 |
|
| 2015 |
Kelly T, Prah M, Jogal S, Maheshwari M, Lew S, Schmainda K. OT-01 * EFFECTIVENESS OF PERFUSION AND DIFFUSION IMAGING FOR GRADING PEDIATRIC BRAIN TUMORS Neuro-Oncology. 17: iii28-iii29. DOI: 10.1093/Neuonc/Nov061.114 |
0.477 |
|
| 2014 |
LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro-Oncology. 16: 1599-606. PMID 25059209 DOI: 10.1093/Neuonc/Nou142 |
0.674 |
|
| 2014 |
Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP. Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. Physiological Genomics. 46: 467-81. PMID 24803679 DOI: 10.1152/Physiolgenomics.00034.2014 |
0.612 |
|
| 2014 |
Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro-Oncology. 16: 880-8. PMID 24431219 DOI: 10.1093/Neuonc/Not216 |
0.406 |
|
| 2014 |
LaViolette PS, Daun MK, Paulson ES, Schmainda KM. Effect of contrast leakage on the detection of abnormal brain tumor vasculature in high-grade glioma. Journal of Neuro-Oncology. 116: 543-9. PMID 24293201 DOI: 10.1007/S11060-013-1318-9 |
0.686 |
|
| 2014 |
Prah M, Al-Gizawiy M, Mueller W, Hoffmann R, Schmainda K. NI-65 * DIFFERENTIATING RADIATION EFFECT AND NECROSIS FROM GLIOBLASTOMA WITH DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) MRI Neuro-Oncology. 16: v152-v152. DOI: 10.1093/Neuonc/Nou264.63 |
0.419 |
|
| 2014 |
Mickevicius N, Carle A, Santarriaga-Escamilla S, Bluemel T, Connelly J, Rand S, Mueller W, Schmainda K, LaViolette P. NI-58 * LOCATION OF GLIOBLASTOMA INTERSECTIING WHITE MATTER TRACTS PREDICT PATIENT PROGNOSIS AND RESPONSE TO BEVACIZUMAB PRIOR TO THERAPY Neuro-Oncology. 16: v151-v151. DOI: 10.1093/Neuonc/Nou264.56 |
0.693 |
|
| 2014 |
Al-Gizawiy M, Prah M, Mueller W, LaViolette P, Schmainda K. NI-03 * DSC-MRI MEASURES OF rCBV PREDICT TUMOR CHARACTERISTICS BEYOND STANDARD HISTOPATHOLOGY Neuro-Oncology. 16: v138-v138. DOI: 10.1093/Neuonc/Nou264.3 |
0.702 |
|
| 2014 |
Cohen A, Pechman K, Schmainda K. NI-14 * THE DIFFUSION WEIGHTED IMAGING DERIVED INFLECTION B-VALUE AS A POTENTIAL MARKER FOR BRAIN TUMOR HETEROGENEITY Neuro-Oncology. 16: v140-v140. DOI: 10.1093/Neuonc/Nou264.13 |
0.434 |
|
| 2013 |
Liu X, Pillay S, Li R, Vizuete JA, Pechman KR, Schmainda KM, Hudetz AG. Multiphasic modification of intrinsic functional connectivity of the rat brain during increasing levels of propofol. Neuroimage. 83: 581-92. PMID 23851326 DOI: 10.1016/J.Neuroimage.2013.07.003 |
0.307 |
|
| 2013 |
Boxerman JL, Paulson ES, Prah MA, Schmainda KM. The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: Implications for clinical applications American Journal of Neuroradiology. 34: 1364-1369. PMID 23413249 DOI: 10.3174/Ajnr.A3477 |
0.429 |
|
| 2013 |
Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM. Effects of perfusion on diffusion changes in human brain tumors. Journal of Magnetic Resonance Imaging : Jmri. 38: 868-75. PMID 23389889 DOI: 10.1002/Jmri.24042 |
0.659 |
|
| 2013 |
LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro-Oncology. 15: 442-50. PMID 23382287 DOI: 10.1093/Neuonc/Nos323 |
0.679 |
|
| 2013 |
Pechman KR, Lozen A, Al-Gizawiy M, Schmainda K, Chitambar CR. Abstract 5606: Gallium maltolate inhibits brain tumor volume and blood volume in xenograft model. Cancer Research. 73: 5606-5606. DOI: 10.1158/1538-7445.Am2013-5606 |
0.439 |
|
| 2012 |
Schmainda KM. Diffusion-weighted MRI as a biomarker for treatment response in glioma. Cns Oncology. 1: 169-80. PMID 23936625 DOI: 10.2217/Cns.12.25 |
0.439 |
|
| 2012 |
Boxerman JL, Prah DE, Paulson ES, Machan JT, Bedekar D, Schmainda KM. The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. Ajnr. American Journal of Neuroradiology. 33: 1081-7. PMID 22322605 DOI: 10.3174/Ajnr.A2934 |
0.71 |
|
| 2012 |
Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM. Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. Magnetic Resonance in Medicine. 68: 1266-72. PMID 22213469 DOI: 10.1002/Mrm.23315 |
0.468 |
|
| 2012 |
Barr A, Collier W, Piacentine L, Douville K, Durgerian S, LaViolette P, Sabsevitz D, Schmainda K, Chitambar CR, Bloom A. Abstract 2654: A prospective study of the effects of adjuvant chemotherapy (CT) on cognition and brain function in breast cancer patients Cancer Research. 72: 2654-2654. DOI: 10.1158/1538-7445.Am2012-2654 |
0.594 |
|
| 2011 |
Bedekar D, Schmainda KM, Rand S, Connelly JM, Malkin MG, Paulson E, Mueller W. Delta T1 (dT1) method as a tool to evaluate tumor progression in patients with brain cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21056. PMID 28022194 DOI: 10.1200/Jco.2011.29.15_Suppl.E21056 |
0.438 |
|
| 2011 |
Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 1151-61. PMID 21856685 DOI: 10.1093/Neuonc/Nor079 |
0.442 |
|
| 2011 |
Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM. Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. Journal of Neuro-Oncology. 105: 233-9. PMID 21533524 DOI: 10.1007/S11060-011-0591-8 |
0.441 |
|
| 2011 |
Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM. Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 65: 1131-43. PMID 21413079 DOI: 10.1002/Mrm.22688 |
0.649 |
|
| 2011 |
LaViolette PS, Rand SD, Ellingson BM, Raghavan M, Lew SM, Schmainda KM, Mueller W. 3D visualization of subdural electrode shift as measured at craniotomy reopening. Epilepsy Research. 94: 102-9. PMID 21334178 DOI: 10.1016/J.Eplepsyres.2011.01.011 |
0.578 |
|
| 2011 |
Darpolor MM, Molthen RC, Schmainda KM. Multimodality imaging of abnormal vascular perfusion and morphology in preclinical 9L gliosarcoma model. Plos One. 6: e16621. PMID 21305001 DOI: 10.1371/Journal.Pone.0016621 |
0.416 |
|
| 2011 |
LaViolette PS, Rand SD, Raghavan M, Ellingson BM, Schmainda KM, Mueller W. Three-dimensional visualization of subdural electrodes for presurgical planning. Neurosurgery. 68: 152-60; discussion 1. PMID 21206319 DOI: 10.1227/Neu.0B013E31820783Ba |
0.565 |
|
| 2011 |
Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. Journal of Neuro-Oncology. 102: 95-103. PMID 20798977 DOI: 10.1007/S11060-010-0293-7 |
0.721 |
|
| 2010 |
Bedekar D, Jensen T, Schmainda KM. Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. Magnetic Resonance in Medicine. 64: 907-13. PMID 20806381 DOI: 10.1002/Mrm.22445 |
0.368 |
|
| 2010 |
Prah DE, Paulson ES, Nencka AS, Schmainda KM. A simple method for rectified noise floor suppression: Phase-corrected real data reconstruction with application to diffusion-weighted imaging. Magnetic Resonance in Medicine. 64: 418-29. PMID 20665786 DOI: 10.1002/Mrm.22407 |
0.722 |
|
| 2010 |
Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. Journal of Magnetic Resonance Imaging : Jmri. 31: 538-48. PMID 20187195 DOI: 10.1002/Jmri.22068 |
0.618 |
|
| 2010 |
Ellingson BM, Rand SD, Malkin MG, Schmainda KM. Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. Journal of Neuro-Oncology. 97: 419-23. PMID 19813078 DOI: 10.1007/S11060-009-0018-Y |
0.509 |
|
| 2010 |
Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, Schmainda KM, Dueck AC, Debbins J, Smith KA, Nakaji P, Eschbacher JM, Coons SW, Heiserman JE. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. Ajnr. American Journal of Neuroradiology. 31: 40-8. PMID 19749223 DOI: 10.3174/Ajnr.A1787 |
0.385 |
|
| 2010 |
Hu LS, Baxter LC, Pinnaduwage DS, Jensen T, Dueck AC, Eschbacher JM, Heiserman JE, Karis JP, Debbins J, Schmainda KM. Accuracy of a modeling algorithm to optimize perfusion MRI detection of glioma recurrence. Journal of Clinical Oncology. 28: 2081-2081. DOI: 10.1200/Jco.2010.28.15_Suppl.2081 |
0.404 |
|
| 2009 |
Jensen TR, Schmainda KM. Computer-aided detection of brain tumor invasion using multiparametric MRI. Journal of Magnetic Resonance Imaging : Jmri. 30: 481-9. PMID 19711398 DOI: 10.1002/Jmri.21878 |
0.441 |
|
| 2008 |
Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 249: 601-13. PMID 18780827 DOI: 10.1148/Radiol.2492071659 |
0.447 |
|
| 2008 |
Pathak AP, Ward BD, Schmainda KM. A novel technique for modeling susceptibility-based contrast mechanisms for arbitrary microvascular geometries: the finite perturber method. Neuroimage. 40: 1130-43. PMID 18308587 DOI: 10.1016/J.Neuroimage.2008.01.022 |
0.393 |
|
| 2007 |
Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magnetic Resonance in Medicine. 57: 680-7. PMID 17390352 DOI: 10.1002/Mrm.21193 |
0.682 |
|
| 2006 |
Bennett KM, Hyde JS, Schmainda KM. Water diffusion heterogeneity index in the human brain is insensitive to the orientation of applied magnetic field gradients. Magnetic Resonance in Medicine. 56: 235-9. PMID 16929466 DOI: 10.1002/Mrm.20960 |
0.388 |
|
| 2006 |
Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Ajnr. American Journal of Neuroradiology. 27: 859-67. PMID 16611779 |
0.347 |
|
| 2005 |
Quarles CC, Ward BD, Schmainda KM. Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magnetic Resonance in Medicine. 53: 1307-16. PMID 15906288 DOI: 10.1002/Mrm.20497 |
0.704 |
|
| 2005 |
Quarles CC, Krouwer HG, Rand SD, Schmainda KM. Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters. Technology in Cancer Research & Treatment. 4: 245-9. PMID 15896079 DOI: 10.1177/153303460500400303 |
0.713 |
|
| 2005 |
Ahunbay E, Schmainda K, Lund R, Prost R, Ulmer J, Alaly J, Deasy J, Schultz C, Li X. SU-FF-J-105: Tools for Voxel-By-Voxel Correlation of Radiotherapy Dose and MR Signals From Multiple Physiological/functional MRI Modalities Medical Physics. 32: 1944-1944. DOI: 10.1118/1.1997651 |
0.398 |
|
| 2005 |
Lund R, Rand S, Krouwer H, Schultz C, Schmainda K. Using rCBV to Distinguish Radiation Necrosis from Tumor Recurrence in Malignant Gliomas International Journal of Radiation Oncology*Biology*Physics. 63: S65-S66. DOI: 10.1016/J.Ijrobp.2005.07.114 |
0.369 |
|
| 2004 |
Bennett KM, Hyde JS, Rand SD, Bennett R, Krouwer HG, Rebro KJ, Schmainda KM. Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain. Magnetic Resonance in Medicine. 52: 994-1004. PMID 15508160 DOI: 10.1002/Mrm.20286 |
0.441 |
|
| 2004 |
Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD, Pathak AP, Ulmer JL, Badruddoja MA, Baddrudoja MA, Krouwer HG. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. Ajnr. American Journal of Neuroradiology. 25: 1524-32. PMID 15502131 |
0.307 |
|
| 2004 |
Ulmer JL, Hacein-Bey L, Mathews VP, Mueller WM, DeYoe EA, Prost RW, Meyer GA, Krouwer HG, Schmainda KM. Lesion-induced pseudo-dominance at functional magnetic resonance imaging: implications for preoperative assessments. Neurosurgery. 55: 569-79; discussion 5. PMID 15335424 DOI: 10.1227/01.Neu.0000134384.94749.B2 |
0.302 |
|
| 2003 |
Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro-Oncology. 5: 235-43. PMID 14565159 DOI: 10.1215/S1152851703000073 |
0.413 |
|
| 2003 |
Bennett KM, Schmainda KM, Bennett RT, Rowe DB, Lu H, Hyde JS. Characterization of continuously distributed cortical water diffusion rates with a stretched-exponential model. Magnetic Resonance in Medicine. 50: 727-34. PMID 14523958 DOI: 10.1002/Mrm.10581 |
0.347 |
|
| 2003 |
Pathak AP, Rand SD, Schmainda KM. The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (DeltaR2*) and contrast agent (MION) dose. Journal of Magnetic Resonance Imaging : Jmri. 18: 397-403. PMID 14508775 DOI: 10.1002/Jmri.10371 |
0.421 |
|
| 2003 |
Abu-Hajir M, Rand SD, Krouwer HG, Schmainda KM. Noninvasive assessment of neoplastic angiogenesis: the role of magnetic resonance imaging. Seminars in Thrombosis and Hemostasis. 29: 309-15. PMID 12888935 DOI: 10.1055/S-2003-40969 |
0.452 |
|
| 2002 |
Kim YR, Rebro KJ, Schmainda KM. Water exchange and inflow affect the accuracy of T1-GRE blood volume measurements: Implications for the evaluation of tumor angiogenesis Magnetic Resonance in Medicine. 47: 1110-1120. PMID 12111957 DOI: 10.1002/Mrm.10175 |
0.419 |
|
| 2001 |
Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 46: 735-47. PMID 11590650 DOI: 10.1002/Mrm.1252 |
0.457 |
|
| Show low-probability matches. |